Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Operating Leases: 2018-2025

Historic Operating Leases for Cytokinetics (CYTK) over the last 6 years, with Sep 2025 value amounting to $110.7 million.

  • Cytokinetics' Operating Leases fell 3.57% to $110.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.7 million, marking a year-over-year decrease of 3.57%. This contributed to the annual value of $112.6 million for FY2024, which is 6.51% down from last year.
  • Cytokinetics' Operating Leases amounted to $110.7 million in Q3 2025, which was down 0.34% from $111.0 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Operating Leases ranged from a high of $126.9 million in Q4 2022 and a low of $85.6 million during Q1 2021.
  • In the last 3 years, Cytokinetics' Operating Leases had a median value of $116.7 million in 2024 and averaged $117.2 million.
  • In the last 5 years, Cytokinetics' Operating Leases soared by 25,406.59% in 2021 and then declined by 6.51% in 2024.
  • Over the past 5 years, Cytokinetics' Operating Leases (Quarterly) stood at $112.2 million in 2021, then grew by 13.07% to $126.9 million in 2022, then fell by 5.10% to $120.4 million in 2023, then declined by 6.51% to $112.6 million in 2024, then declined by 3.57% to $110.7 million in 2025.
  • Its Operating Leases was $110.7 million in Q3 2025, compared to $111.0 million in Q2 2025 and $113.4 million in Q1 2025.